SK Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
SK Biopharmaceuticals has a total shareholder equity of ₩574.0B and total debt of ₩150.7B, which brings its debt-to-equity ratio to 26.3%. Its total assets and total liabilities are ₩1,036.8B and ₩462.8B respectively. SK Biopharmaceuticals's EBIT is ₩96.3B making its interest coverage ratio 179.6. It has cash and short-term investments of ₩324.5B.
Key information
26.26%
Debt to equity ratio
₩150.72b
Debt
| Interest coverage ratio | 179.6x |
| Cash | ₩324.49b |
| Equity | ₩573.98b |
| Total liabilities | ₩462.83b |
| Total assets | ₩1.04t |
Recent financial health updates
Recent updates
SK Biopharmaceuticals' (KRX:326030) Shareholders Should Assess Earnings With Caution
Mar 14
Is SK Biopharmaceuticals (KRX:326030) Using Too Much Debt?
Feb 21SK Biopharmaceuticals Co., Ltd.'s (KRX:326030) Share Price Matching Investor Opinion
Jan 23SK Biopharmaceuticals Co., Ltd. (KRX:326030) Shares Could Be 47% Below Their Intrinsic Value Estimate
Nov 27There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings
Aug 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump
Aug 21Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22Financial Position Analysis
Short Term Liabilities: A326030's short term assets (₩651.4B) exceed its short term liabilities (₩396.3B).
Long Term Liabilities: A326030's short term assets (₩651.4B) exceed its long term liabilities (₩66.6B).
Debt to Equity History and Analysis
Debt Level: A326030 has more cash than its total debt.
Reducing Debt: A326030 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: A326030's debt is well covered by operating cash flow (63%).
Interest Coverage: A326030's interest payments on its debt are well covered by EBIT (179.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 01:11 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SK Biopharmaceuticals Co., Ltd. is covered by 24 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dae Woong Yoo | Bookook Securities Co. Ltd |
| Heejin Lim | Citigroup Inc |
| Citi Research | Citigroup Inc |